TABLE 1.
Comparison of Cyclophosphamide Doses, Local Therapies, Local Failure Rates, and Patient Outcomes in Trials on Rhabdomyosarcoma
| Study | Cyclophosphamide Dose,
g/m2 |
Local Therapy
Characteristics |
Local Failure Rate,
% |
Outcomes: FFS/EFS and OS |
||||
|---|---|---|---|---|---|---|---|---|
| Per Cycle | Cumulative Dose | Timing, wk | DPE, % Group III | PM >5 cm | Group III Emb/Alv | |||
| IRSG-IV5 | 2.2 | 26.4 | 9 | 0.8 | 16 | 34 | 13 | 5-y FFS: 70% 5-y OS: 75% |
| D98036 | 2.2 | 25.1-30.8 | 12 | 45 | 19.5 | 25 | 19.4/17.7 | 4-y EFS: 68%-73% 5-y OS: 79% |
| ARST05317 | 1.2 | 8.4-16.8 | 4 | 16 | 27.7 | 32.3 | 27.9/20.2 | 4-y EFS: 59%-63% 4-y OS: 72%-73% |
| MSKCC | 1.2-2.2 | 10-24 | 13 | NR | 12.5 | NR | 10.6/6.8 | 2-y EFS: 74.6% 2-y OS: 84.1% |
| RMS 2005 | ≈1.5 + maint | ≈17.7 | 13 | NR | NR | NR | NR | 3-y EFS: 78.4% (maint) vs 72.3%3-y OS: 87.3% (maint) vs 77.4% |
| ARST1431 | 1.2 + maint | 12.6 | 13 | — | — | — | — | — |
Abbreviations: DPE, delayed primary excision; EFS, event-free survival; Emb/Alv, embryonal/alveolar; FFS, failure-free survival; IRSG-IV, Intergroup Rhabdomyosarcoma Study Group IV; maint, maintenance; MSKCC, Memorial Sloan Kettering Cancer Center; NR, not reported; PM, parameningeal; OS overall survival; RMS 2005, Rhabdomyosarcoma 2005.